日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Decay of driver mutations shapes the landscape of intestinal transformation.

驱动基因突变的衰减塑造了肠道转化的格局。

Lourenço Filipe C, Sadien Iannish D, Wong Kim, Adler Sam, Sawle Ashley, Santana Leonor Schubert, Hazelwood Lee, Giavara Giada, Nicholson Anna M, Eldridge Matthew D, Maka Noori, Lynch Gerard, McSorley Stephen T, Edwards Joanne, Kemp Richard, Adams David J, Winton Douglas J

Neuronal subtype governs amyloid structure, cellular response, and cognitive outcome in genetically targeted APP mouse models.

在基因靶向 APP 小鼠模型中,神经元亚型决定淀粉样蛋白结构、细胞反应和认知结果。

Perez Gabriella A, Lai Zoe, Edwards Iii George A, Dundee Jacob M, Leahy Shannon N, Qi Chuangye, Qi Yanyan, Park Ye-Jin, Lu Tzu-Chiao, Uddin M Danish, Zhao Rong, Zheng Hui, Li Hongjie, Jankowsky Joanna L

CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer

CRISPR-Cas9筛选揭示胰腺癌中KRAS抑制的耐药机制

Long, Szu-Aun; Todd, Haley; Goodhart, Grace; Chang, Wen-Hsuan; Amparo, Amber M; Bridgens, Rachel; Dilly, Julien; Park, Se Jun; Beal, Robert M; Shehadeh, Sara M; Satyadi, Megan A; Trivedi, Vidushi K; Ackermann, Sarah E; Mukherjee, Raivath; Goodwin, Craig M; Edwards, A Cole; Stalnecker, Clint A; Greis, Kenneth D; Aguirre, Andrew J; Hobbs, G Aaron; Bryant, Kirsten L; Ahmad, Syed A; Cox, Adrienne D; Der, Channing J; Waters, Andrew M

Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer.

DNA损伤反应缺陷是ESR1突变型乳腺癌的一个可靶向治疗弱点。

Herzog Sarah K, Stevens Jessica H, Gu Guowei, Grimm Sandra L, Cardoza Kloma, Hawkins Autumn G M, Lin Hangqing, Ramos Daniela, Beyer Amanda R, Edwards David G, Dustin Derek, Yang Harry J, Liang Nicole, Khan Ashfia F, Bawa-Khalfe Tasneem, McGrail Daniel J, Lin Shiaw-Yih, Coarfa Cristian, Fuqua Suzanne A W

Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development.

Env抗体共同进化表明B细胞启动是HIV V2顶端广泛中和抗体发展的主要瓶颈。

Habib Rumi, Roark Ryan S, Li Hui, Connell Andrew Jesse, Hogarty Michael P, Wagh Kshitij, Wang Shuyi, Marchitto Lorie, Skelly Ashwin N, Carey John W, Sowers Kirsten J, Ayyanathan Kasirajan, Plante Samantha J, Bibollet-Ruche Frederic, Park Younghoon, Agostino Colby J, Singh Ajay, Martella Christian L, Lewis Emily, Rando Juliette M, Chohan Neha, Lora Jinery, Ding Wenge, Campion Mary S, Zhao Chengyan, Liu Weimin, Li Yingying, Li Xuduo, Liang Bo, Chowdhury Rohan Roy, Amereh Khaled, Van Itallie Elizabeth, Sheng Zizhang, Ghosh Amrit R, Bar Katharine J, Williams Wilton B, Wiehe Kevin, Saunders Kevin O, Edwards Robert J, Cain Derek W, Lewis Mark G, Batista Facundo D, Burton Dennis R, Andrabi Raiees, Kulp Daniel W, Haynes Barton F, Korber Bette, Shapiro Lawrence, Kwong Peter D, Hahn Beatrice H, Shaw George M

Inflammation- and resolution-programmed myeloid circuits govern therapeutic resistance in epithelial and mesenchymal triple-negative breast cancer

炎症和消退程序性髓系回路调控上皮性和间质性三阴性乳腺癌的治疗耐药性

Yu, Liqun; Rivas, Charlotte; Liu, Fengshuo; Shen, Yichao; Wu, Ling; Xu, Zhan; Ding, Yunfeng; Hao, Xiaoxin; Zhang, Weijie; Chan, Hilda L; Liu, Jun; Wei, Bo; Gao, Yang; Becerra-Dominguez, Luis; Wu, Yi-Hsuan; Wang, Siyue; Lee, Tobie D; Li, Xuan; Chen, Xiang; Edwards, David G; Zhang, Xiang H-F

Intracerebroventricular SPAST-AAV9 gene therapy prevents manifestation of symptoms in a mouse model of SPG4 hereditary spastic paraplegia.

脑室内 SPAST-AAV9 基因治疗可预防 SPG4 遗传性痉挛性截瘫小鼠模型出现症状。

Piermarini Emanuela, Guha Shrobona, Qiang Liang, Gray-Edwards Heather, Sena-Esteves Miguel, Baas Peter W

Management of brain-heart multimorbidity: a clinical practice guideline

脑心多重疾病的管理:临床实践指南

Edwards, Jodi D; Li, Zhe; McFarlane, Philip; Rabi, Doreen M; Gilbert, Jeremy; Bajaj, Harpreet S; MacIntosh, Bradley J; Bittman, Jesse; Feldman, Ross D; Dresser, George; Terenzi, Kristin; Swartz, Rick; Gabor, Jonathan; Pearson, Glen J; Selby, Peter; Wharton, Sean; Warburton, Darren E R; Pakhalé, Smita; Styra, Rima; Baker, Brian; Tu, Karen; Hawkins, Michael; Stone, James A; Vaillancourt, Tracy; Poon, Stephanie; Virani, Sean A; Jain, Rahul; Jones, Peter Hayward; Sandhu, Roopinder K; Ganesh, Aravind; Andrade, Jason G; Stern, Sol; Habert, Jeffrey; Rivard, Léna; Roumeliotis, Paul; Udell, Jacob A; Campbell, Tavis; Bacon, Simon L; Trudeau, Luc; Keshavjee, Karim; Pham, Thuy; Cheng, Gemma; Lewis, Krystina B; Maar, Marion; Stacey, Dawn; Oldenburg, Brian; Dhukai, Abida R; Pasricha, Sachin V; Sherifali, Diana; Racey, Megan; Hua-Stewart, Diane; Gravel, Christopher A; Lewis, Meghan; Mehta, Sumali; Hill, Michael D; Haider, Nazia; Lindsay, Patrice; Liu, Peter; Tobe, Sheldon W

Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics.

通过多重定量蛋白质组学鉴定 VALOR 临床试验脑脊液中托福生帕金森反应生物标志物。

Guise Amanda J, Ferber Kyle L, Young Damon, Edwards Amanda L, Sabouri Somayeh, Fraser Kyle B, Milliman Eric, Plowey Edward D, Zoghbi Jad, Fradette Stephanie M, Graham Danielle L

Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development.

针对 EBV gp350 和 gp42 的转基因小鼠来源的人类单克隆抗体为治疗开发提供了基础。

Chhan Crystal B, Lang Kevin, Davis Amelia R, Wan Yu-Hsin, Aldridge Nicholas T, Kher Gargi, Scharffenberger Samuel C, Hardy Samantha R, Iureniev Roman, Giltiay Natalia V, Edwards Kristina R, Radtke Stefan, Kiem Hans-Peter, Pancera Marie, McGuire Andrew T